Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AstraZeneca

Infants should get a new drug to protect them against a respiratory virus that sends tens of thousands of American children to the hospital each year, heath advisers recommended Thursday.

CDC panel says babies should get new drug that prevents RSV

The U.S. Centers for Disease Control and Prevention said on Thursday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.

US CDC approves Sanofi-AstraZeneca's preventive RSV therapy for babies

U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus ™ ( nirsevimab-alip ) to protect infant s against RSV disease

Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease

Sanofi (NASDAQ:SNY ) Q2 2023 Earnings Call Q2 2023 Earnings Call Transcript July 28, 2023 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head of Investor Relations Paul Hudson - Chief Executive Officer Dietmar Berger - Global Head of R&D Bill Sibold - Executive Vice President Specialty Care & President, Sanofi North America Thomas Triomphe - Executive Vice President, Vaccines Olivier Charmeil - Executive Vice President, General Medicines Julie van Ongevalle - Executive Vice President, Consumer Healthcare Jean-Baptiste de Chatillon - Executive Vice President, Chief Financial Officer Conference Call Participants Emily Field - Barclays Richard Vosser - JPMorgan Peter Welford - Jefferies Seamus Fernandez - Guggenheim Peter Verdult - Citi Thibault Boutherin - Morgan Stanley Graham Parry - BofA David Risinger - Leerink Gary Steventon - Exane BNP Jo Walton - Credit Suisse Eva Schaefer-Jansen Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's Second Quarter 2023 Results followed by Q&A session.

Sanofi (SNY) Q2 2023 Earnings Call Transcript

Sanofi (SNY) beats second-quarter estimates for earnings but misses the same for sales. It raises the projected earnings growth range for 2023.

Sanofi (SNY) Beats on Q2 Earnings, Misses Sales, Stock Down

Online availability of Sanofi's half-year financial report for 202 3 Paris , July 28, 2023. Sanofi announces that its half-year financial report for the period ending June 30, 2023 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

Press release: Online availability of Sanofi's half-year financial report for 2023

French drugmaker Sanofi on Friday increased its guidance for full-year earnings on strong sales of anti-inflammatory treatment Dupixent and promising new drug launches.

Sanofi lifts earnings outlook on Dupixent sales, new drug launches

Sanofi to acquire Qunol ® , a fast -growing U.S. brand in the healthy aging segment Transaction brings Qunol®, a trusted, profitable double-digit growth and market-leading brand in health & wellness to Sanofi's CHC U.S. portfolio  Addition of Qunol's CoQ10 and Turmeric products strengthens Sanofi's CHC Vitamin, Mineral and Supplements category, one of the largest and fastest-growing consumer health categories in the U.S. Paris, July 28 , 2023. Sanofi announces today it has entered into a definitive agreement to acquire ownership of Qunol®, a U.S.-based, market-leading brand in health & wellness.

Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment

First large consumer healthcare company to earn B Corp Certification Rigorous certification marks significant progress by maker of Allegra®, Icy Hot® BRIDGEWATER, N.J. , July 25, 2023 /PRNewswire/ -- After making strides in environmental sustainability and social impact commitments, Sanofi Consumer Healthcare North America is pleased to announce it has earned B Corp Certification.

Sanofi Consumer Healthcare North America Earns B Corp Certification in Recognition of Environmental, Social Impact

British American Tobacco

Anheuser-Busch InBev

General Motors

Lam Research

Shell PLC

Stellantis N.V. 

While it's usually the smaller enterprises that offer screaming buy opportunities for discerning speculators, sometimes even the best blue-chip stocks to buy don't get the attention they deserve. With thousands upon thousands of publicly traded securities available, it's inevitable that some ideas will slip through the cracks.

7 Blue-Chip Stocks That Are Screaming Buys Right Now: July 2023

Sanofi said it is working with a CDC panel to include Beyfortus on the childhood immunization schedule and the Vaccines for Children Program.

Sanofi expects infant RSV shot to roll out before respiratory virus season this fall

Sanofi has shown strong growth in 2023, with an 11.9% YoY increase in EPS and a target of $10 billion in sales. The share price has risen nearly 10% YTD. The company's margins are impressive, with gross margins at nearly 70%. The FCF margin is strong, indicating a potential for higher dividend yield as the payout ratio is currently at 42%. Despite trading above its intrinsic value by around 29%, Sanofi is considered a good long-term investment due to its solid retention of margins and potential for dividend growth.

Sanofi: Powering Up And Offering Investors A Lot Of Potentials

Following FDA approval, Sanofi (SNY)/AstraZeneca's (AZN) Beyfortus is the first RSV antibody approved to protect all infants. The companies plan to make it available ahead of the upcoming RSV season.

Sanofi (SNY), AstraZeneca's RSV Antibody Gets FDA Nod in Infants

WASHINGTON (AP) — U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.

New drug to protect babies and toddlers from RSV gets FDA approval ahead of cold season

RSV in infants often leads to the development of pneumonia or bronchiolitis—conditions that can result in emergency visits.

FDA Approves Antibody For RSV After Challenging 2022 Season

The U.S. Food and Drug Administration on Monday approved a Sanofi SNY, +0.28% and AstraZeneca PLC AZN, -0.60% respiratory syncytial virus vaccine for newborns and infants. The RSV vaccine, Beyfortus, was approved for prevention of RSV lower respiratory tract disease in babies entering their first RSV vaccine as well as children up to two years old who remain vulnerable to severe RSV, the FDA said in a release.

FDA approves Sanofi and AstraZeneca infant RSV vaccine

While the virus often leads to mild, coldlike symptoms, it is the leading cause of hospitalization of infants in the U.S.

FDA Approves First RSV Drug to Protect All Infants

Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition. Nirsevimab is administered either before or during an infant's first RSV season.

FDA approves AstraZeneca, Sanofi shot that protects infants and toddlers against RSV

U.S. Food and Drug Administration said on Monday it had approved Sanofi and partner AstraZeneca's antibody therapy to prevent respiratory syncytial virus (RSV) in infants and toddlers.

US FDA approves Sanofi-AstraZeneca's preventive RSV therapy for babies

FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease Beyfortus ™ is the first monoclonal antibody approved to protect all infants through their first RSV season Across all clinical endpoints, a single dose of Beyfortus delivered high, consistent and sustained efficacy and favorable safety against RSV disease Approval also includes use for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season Paris, July 17 , 2023. The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca's Beyfortus™ (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease

ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe and Sanofi will collaborate to combine Scribe's CRISPR X-Editing technologies with Sanofi's targeted non-viral delivery technologies.

Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

This is Why Sanofi (SNY) is a Great Dividend Stock

Baidu

Novozymes A/S

Reckitt Benckiser Group PLC

Tencent Holdings Limited

Taiwan Semiconductor Manufacturing

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth it.

International Wide-Moat Stocks On Sale - The July 2023 Heat Map

The 21-valent pneumococcal conjugate vaccine candidate, GBP410 (also known as SP0202), demonstrates positive safety and immunogenicity data from the Phase II study. SK bioscience and Sanofi plan to start Phase III in H1 2024.

SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

Sanofi, a global pharmaceutical company, has upside potential due to its low current valuation, a solid pipeline of drugs, and potential AI-driven gains later on. While profits may dip this year, EPS gains care of its blockbuster Dupixent drug result in a favorable normalized PEG ratio. A foray into AI is a bullish catalyst, though Sanofi's chart is currently lackluster.

News for Sanofi Stock (SNY)